ABSTRACT
We diverted bile and pancreatic juice from jejunal blind loops of different lengths in conscious rats to see if the pancreatic secretory response was dependent on the length of the jejunal blind loop. Short-term bile and pancreatic juice diversion from a short jejunal blind loop, representing only 8-10% of the total length of the small intestine, stimulated a significant increase in pancreatic exocrine secretion. Short-term bile and pancreatic juice diversion from jejunal blind loops of increasing length resulted in a progressive decrease in the pancreatic secretory response to diversion (i.e., there appears to be a length-dependent inhibition of the pancreatic secretory response to short-term bile and pancreatic juice diversion from the jejunum). Cholinergic receptor blockade with atropine eliminated this length-dependent inhibition of pancreatic exocrine secretion during short-term bile and pancreatic juice diversion. In contrast to what was observed with short-term bile and pancreatic juice diversion, there was a length-dependent increase in pancreatic secretion during long-term bile and pancreatic juice diversion. The jejunal-bypass rat model can facilitate the investigation of the intestinal mechanisms mediating feedback regulation of pancreatic exocrine secretion.
Subject(s)
Bile/metabolism , Jejunum/physiology , Pancreas/metabolism , Pancreatic Juice/metabolism , Animals , Atropine/pharmacology , Devazepide/pharmacology , Jejunum/surgery , Male , Pancreas/drug effects , Rats , Rats, Wistar , Receptors, Cholecystokinin/antagonists & inhibitorsABSTRACT
A luminal cholecystokinin releasing factor (LCRF), has been purified from intestinal secretion and found to have a mass of 8136 daltons. The amino-terminal 41 residues have been sequenced. Previous studies showed that intraduodenal infusion of the synthetic amino-terminal 35 amino acid peptide, LCRF1-35 significantly stimulated pancreatic protein and fluid secretion in conscious rats, but the peptide did not stimulate amylase release from isolated, dispersed pancreatic acini. In the present study, several fragments of LCRF were synthesized and tested for CCK-releasing activity (pancreatic protein secretion) to determine whether shorter fragments of LCRF exhibit the characteristic biological activity of native LCRF and synthetic LCRF1-35. Compounds tested were LCRF1-41, LCRF1-35, LCRF1-65 and LCRF11-25. Of the fragments shorter than LCRF1-35, only LCRF11-25 but not LCRF1-6 had significant CCK releasing activity. LCRF1-41 was equivalent to LCRF1-35 in potency and efficacy. Intravenous and intraduodenal infusion of LCRF1-35 elicited nearly identical dose-response curves.
Subject(s)
Growth Substances/pharmacology , Intercellular Signaling Peptides and Proteins , Pancreas/drug effects , Animals , Binding Sites , Cholecystokinin/drug effects , Cholecystokinin/metabolism , Duodenum , Growth Substances/administration & dosage , Growth Substances/metabolism , Infusions, Intravenous , Male , Pancreas/metabolism , Peptide Fragments/administration & dosage , Peptide Fragments/metabolism , Peptide Fragments/pharmacology , Proteins/drug effects , Proteins/metabolism , Rats , Rats, Wistar , Trypsin/metabolism , Trypsin Inhibitor, Kazal PancreaticABSTRACT
The purpose of this study was to examine the distribution and localization of an intestinal cholecystokinin (CCK)-releasing factor, called luminal CCK-releasing factor (LCRF), in the gastrointestinal tract and pancreas of the rat. RIA analysis indicates that LCRF immunoreactivity is found throughout the gut including the pancreas, stomach, duodenum, jejunum, ileum, and colon with the highest levels in the small intestine. Immunohistochemistry analysis shows LCRF immunoreactivity staining in intestinal villi, Brunner's glands of the duodenum, the duodenal myenteric plexus, gastric pits, pancreatic ductules, and pancreatic islets. These results indicate potential sources for secretagogue-stimulated release of luminal LCRF and support the hypothesis that LCRF is secreted into the intestinal lumen to stimulate CCK release from mucosal CCK cells.
Subject(s)
Digestive System/metabolism , Growth Substances/metabolism , Intercellular Signaling Peptides and Proteins , Animals , Immunohistochemistry/methods , Male , Pancreas/metabolism , Radioimmunoassay , Rats , Rats, Sprague-Dawley , Staining and Labeling , Tissue Distribution , Trypsin Inhibitor, Kazal PancreaticABSTRACT
A cholecystokinin (CCK)-releasing peptide, luminal CCK-releasing factor (LCRF), has been purified from rat jejunal secretion. Amino acid analysis and mass spectral analysis showed that the purified peptide is composed of 70-75 amino acid residues and has a mass of 8,136 Da. Microsequence analysis of LCRF yielded an amino acid sequence for the amino-terminal 41 residues. To determine the biologically active region of the molecule, a peptide was synthesized consisting of the amino-terminal 35 amino acids of LCRF. In this study, intraduodenal infusion of LCRF-(1-35) significantly stimulated pancreatic secretion in conscious rats. The dose-response curves to LCRF-(1-35) and to monitor peptide were similar and biphasic, with higher doses producing submaximal pancreatic secretory responses. The CCK-A receptor antagonist MK-329 abolished the pancreatic secretory response to intraduodenally infused LCRF-(1-35). These results demonstrate that LCRF biological activity is contained within the amino-terminal 35-amino acid portion of LCRF, and this fragment may be useful for investigating the role of LCRF in gastrointestinal function.
Subject(s)
Gastrointestinal Hormones/pharmacology , Growth Substances/pharmacology , Intercellular Signaling Peptides and Proteins , Pancreas/metabolism , Pancreatic Juice/metabolism , Peptide Fragments/pharmacology , Animals , Benzodiazepinones/pharmacology , Devazepide , Duodenum , Hormone Antagonists/pharmacology , Male , Molecular Weight , Pancreas/drug effects , Pancreatic Juice/drug effects , Rats , Rats, Wistar , Sincalide/antagonists & inhibitors , Trypsin Inhibitor, Kazal PancreaticABSTRACT
We sought to determine whether the biliary excretion of biotin contributes substantially to the overall excretion of the vitamin in mammals, and hence, whether metabolism by gut microorganisms could account for some metabolism of biotin administered parenterally. [carbonyl-14C]Biotin was injected intravenously into six rats; bile and urine were collected for 24 h after injection. In a study of five pigs, serum and bile were analyzed for endogenous biotin and metabolites. In rat bile and urine, biotin, bisnorbiotin, biotin-d,l-sulfoxide, bisnorbiotin methyl ketone and two unidentified compounds were quantitated. In bile, these six compounds accounted for only 1.9 +/- 0.2% of the administered 14C, but in urine they accounted for 60.6 +/- 4.1%. The metabolite and time profiles in bile were also strikingly different from those in urine. Only biotin, bisnorbiotin and biotin-d,l-sulfoxide were quantitated in pig bile and serum. The concentrations of biotin, bisnorbiotin and biotin-d,l-sulfoxide in bile were 6.9-14.7 times the concentrations in serum. However, the bile to serum ratios of biotin and metabolites were >99% less than those of bilirubin, which is actively excreted. These data provide evidence that the biliary excretion of biotin and metabolites is quantitatively negligible.
Subject(s)
Bile/metabolism , Biotin/metabolism , Animals , Biotin/blood , Biotin/urine , Female , Gallbladder/metabolism , Injections, Intravenous , Male , Rats , Rats, Wistar , Species Specificity , SwineABSTRACT
Cholecystokinin (CCK) secretion in rats and humans is inhibited by pancreatic proteases and bile acids in the intestine. It has been hypothesized that the inhibition of CCK release caused by pancreatic proteases is due to proteolytic inactivation of a CCK-releasing peptide present in intestinal secretion. To purify the putative luminal CCK-releasing factor (LCRF), intestinal secretions were collected by perfusing a modified Thiry-Vella fistula of jejunum in conscious rats. From these secretions, the peptide was concentrated by ultrafiltration followed by low-pressure reverse-phase chromatography and purified by reverse-phase high-pressure liquid chromatography. Purity was confirmed by high-performance capillary electrophoresis. Fractions were assayed for CCK-releasing activity by their ability to stimulate pancreatic protein secretion when infused into the proximal small intestine of conscious rats. Partially purified fractions strongly stimulated both pancreatic secretion and CCK release while CCK receptor blockade abolished the pancreatic response. Amino acid analysis and mass spectral analysis showed that the purified peptide is composed of 70-75 amino acid residues and has a mass of 8136 Da. Microsequence analysis of LCRF yielded an amino acid sequence for 41 residues as follows: STFWAYQPDGDNDPTDYQKYEHTSSPSQLLAPGDYPCVIEV. When infused intraduodenally, the purified peptide stimulated pancreatic protein and fluid secretion in a dose-related manner in conscious rats and significantly elevated plasma CCK levels. Immunoaffinity chromatography using antisera raised to synthetic LCRF-(1-6) abolished the CCK releasing activity of intestinal secretions. These studies demonstrate, to our knowledge, the first chemical characterization of a luminally secreted enteric peptide functioning as an intraluminal regulator of intestinal hormone release.
Subject(s)
Cholecystokinin/metabolism , Duodenum/physiology , Intestinal Mucosa/physiology , Jejunum/physiology , Proteins/isolation & purification , Proteins/pharmacology , Amino Acid Sequence , Animals , Benzodiazepinones/pharmacology , Biological Assay , Chromatography, Affinity , Chromatography, High Pressure Liquid , Devazepide , Hormone Antagonists/pharmacology , Male , Mass Spectrometry , Molecular Sequence Data , Pancreatic Juice/drug effects , Pancreatic Juice/metabolism , Proteins/chemistry , Rats , Rats, Wistar , Reproducibility of ResultsABSTRACT
Exposure to higher levels of fat in the diet increases the secretion of fat-digesting enzymes in pancreatic juice. This study examines the functional consequences of this phenomenon and demonstrates that adapting rats to high fat (triglyceride) loads increases the release of cholecystokinin (CCK) and the pancreatic secretory response to intraduodenal fat. Lipolytic activity in the small intestine was also higher in adapted rats. Exchanging pancreatic juice from unadapted rats with pancreatic juice from adapted rats decreased the response to fat in adapted rats and increased the response to fat in unadapted rats. Infusing oleic acid into unadapted rats stimulated CCK secretion and pancreatic exocrine secretion to levels observed with triglycerides in adapted rats. Pancreatic exocrine secretion in response to intraduodenal fat in rats adapted to a high-fat (20%) diet were significantly higher than the responses seen in rats fed a low-fat (5%) diet. Adaptation to fat increases the pancreatic secretory and plasma CCK responses to fat, apparently by increasing the efficiency of triglyceride digestion and thereby increasing CCK release.
Subject(s)
Adaptation, Physiological , Dietary Fats/metabolism , Dietary Fats/pharmacology , Duodenum/metabolism , Pancreas/metabolism , Animals , Cholecystokinin/blood , Fatty Acids/pharmacology , Injections , Lipolysis , Male , Oleic Acid/pharmacology , Pancreas/drug effects , Pancreatic Juice/physiology , Rats , Rats, Wistar , Secretin/blood , Time Factors , Triglycerides/pharmacologySubject(s)
Amino Acids/pharmacology , Benzodiazepinones/pharmacology , Cholecystokinin/physiology , Dietary Proteins/pharmacology , Enzymes/metabolism , Pancreas/enzymology , Pancreatic Juice/metabolism , Animal Nutritional Physiological Phenomena , Animals , Atropine/pharmacology , Bile/physiology , Cholecystokinin/antagonists & inhibitors , Devazepide , Feedback , Jejunum/physiology , Pancreas/drug effects , Rats , Receptors, Cholecystokinin/antagonists & inhibitorsABSTRACT
The effect of atropine on plasma cholecystokinin (CCK) and pancreatic secretion during intraintestinal infusion of a conventional defined formula liquid diet (Ensure HN, Ross Laboratories, 1.06 kcal/ml) was studied in conscious rats. Rats were prepared with cannulae draining bile and pancreatic juice, which were returned to the duodenum at all times. Pancreatic secretion was monitored during intraduodenal infusion of 0.15 M NaCl for 2 h followed by Ensure HN, both infused at 4.62 ml/h. Rats were infused i.p. with atropine (500 micrograms/kg/h) or vehicle throughout the experiment, beginning 1 h before monitoring of basal pancreatic secretion. Basal and 15 min postprandial plasma CCK concentrations were determined by bioassay. Atropine inhibited basal pancreatic protein secretion by approximately 60%. However, protein secretion during infusion of the diet was not decreased by atropine, due to a larger incremental pancreatic protein secretory response in atropine-treated rats. Plasma CCK 15 min after beginning the diet infusion was significantly increased by atropine (8.09 +/- 1.77 pM in atropine-treated rats versus 3.14 +/- 0.64 pM in controls). The results indicate that rats compensate for loss of cholinergic input to the pancreas by increasing CCK release in response to a meal. This is hypothesized to occur by virtue of reduced feedback inhibition of CCK release due to anticholinergic reduction of basal levels of intestinal protease activity.
Subject(s)
Atropine/pharmacology , Cholecystokinin/metabolism , Food , Pancreas/metabolism , Animals , Cholecystokinin/blood , Male , Pancreas/drug effects , Pancreatic Juice/metabolism , Proteins/metabolism , Rats , Rats, Inbred StrainsABSTRACT
The effect of atropine (100 micrograms/kg/h, i.v.) on plasma cholecystokinin and pancreatic secretion during diversion of bile and pancreatic juice from the intestine was studied in 8 conscious rats equipped with jugular vein, pancreatic, biliary, and duodenal cannulas, and with pyloric ligation and gastric drainage. Diversion of bile and pancreatic juice to the exterior for 4 h significantly increased pancreatic protein and fluid secretion. Atropine delayed the pancreatic response to diversion, but during 4 h of diversion, neither total nor incremental pancreatic protein or fluid secretion was inhibited by atropine. Plasma cholecystokinin levels were elevated after diverting bile and pancreatic juice and were not significantly reduced by atropine (23.0 +/- 6.6 pM vs. 16.0 +/- 3.9 pM at 1.5 h and 17.3 +/- 5.4 pM vs. 13.1 +/- 2.9 pM at 4 h after bile and pancreatic juice diversion; atropine-treated vs. controls, respectively). These results indicate that cholinergic nerves play no important role in feedback regulation of cholecystokinin release and that the previously reported suppressive effect of atropine on the pancreatic response to diversion of bile and pancreatic juice from the intestine was secondary to inhibition of gastric secretion.